{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:40:43Z","timestamp":1773967243561,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>While chemo-radiotherapy improves local control in patients with locally advanced rectal cancer, it can also increase acute hematological toxicity (HT), which leads to poor outcomes. Patients receiving bone marrow radiation have been shown to develop acute HT. However, the safety and efficacy of bone marrow sparing is undetermined. The aim of our study was to explore the feasible dosimetric constraints for pelvic bone marrow (PBM) that can be widely used in rectal cancer patients undergoing chemo-radiotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>112 rectal cancer patients were selected and divided into the PBM sparing IMRT group (60 cases) and the non-PBM sparing IMRT group (52 cases). All patients underwent pelvic radiotherapy with concurrent capecitabine-based chemotherapy. The PBM dosimetric constraints in the PBM sparing IMRT group were set to:V<jats:sub>10<\/jats:sub> \u2264 85%, V<jats:sub>20<\/jats:sub> \u2264 65% and V<jats:sub>30<\/jats:sub> \u2264 45%. An independent sample t test was applied for the dose-volume parameters, and Chi-squared analysis was applied for clinical parameters and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The radiation dose to PBM (V<jats:sub>5<\/jats:sub>~V<jats:sub>45<\/jats:sub>, D<jats:sub>mean<\/jats:sub>, <jats:italic>P<\/jats:italic>&amp;lt;0.05), PBM sub-regions (V<jats:sub>10<\/jats:sub>~V<jats:sub>35<\/jats:sub>, D<jats:sub>mean<\/jats:sub>, <jats:italic>P<\/jats:italic>&amp;lt;0.05) and both femoral heads (V<jats:sub>5<\/jats:sub>~V<jats:sub>40<\/jats:sub>, D<jats:sub>mean<\/jats:sub>, <jats:italic>P<\/jats:italic>&amp;lt;0.05) decreased significantly in the PBM sparing IMRT group compared with that of the non-PBM sparing IMRT group (<jats:italic>P<\/jats:italic>&amp;lt;0.05). There was no significant difference in any dose-volume parameters of the bladder and small bowel in either groups, and none in the planning target volume (PTV) dose homogeneity and conformity (<jats:italic>P<\/jats:italic>&amp;gt;0.05). For acute HT observation, the incidence of grade 3 acute HT (\u03c7<jats:sup>2<\/jats:sup> = 7.094, <jats:italic>P<\/jats:italic>=0.008) was significantly reduced in patients treated with PBM sparing IMRT compared with patients treated with non-PBM sparing IMRT. There was no statistical difference in the incidence of vomiting, diarrhea, fatigue, anorexia, nausea, hand-foot syndrome, cystitis, perianal pain and perianal dermatitis in patients of both groups (<jats:italic>P &amp;gt;<\/jats:italic>0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Applying PBM dosimetric constraints (V<jats:sub>10<\/jats:sub> \u2264 85%, V<jats:sub>20<\/jats:sub> \u2264 65% and V<jats:sub>30<\/jats:sub> \u2264 45%) can significantly reduce the radiation dose to PBM. The patients treated with PBM sparing IMRT had a lower incidence of acute HT compared with those treated with non-PBM sparing IMRT. Applying the PBM dosimetric constraints proposed by our study can benefits the patients with rectal cancer undergoing capecitabine-based chemo-radiotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.646211","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:01:35Z","timestamp":1619107295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Pelvic Bone Marrow Sparing Intensity Modulated Radiation Therapy on Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemo-Radiotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-xia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-li","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21609","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries (Vol 68, Pg 394, 2018)","volume":"70","author":"Bray","year":"2020","journal-title":"Ca\u2013Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.2006.06.7629","article-title":"Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3\u20134 Rectal Cancers: Results of FFCD 9203","volume":"24","author":"Gerard","year":"2006","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3858","article-title":"A Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer","volume":"3","author":"Braendengen","year":"2008","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ARTN CD006041","DOI":"10.1002\/14651858.CD006041.pub3","article-title":"Preoperative Chemoradiation Versus Radiation Alone for Stage II and III Resectable Rectal Cancer","author":"De Caluwe","year":"2013","journal-title":"Cochrane Db Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5506","article-title":"Long\u2013Term Results of a Randomized Trial Comparing Preoperative Short\u2013Course Radiotherapy With Preoperative Conventionally Fractionated Chemoradiation for Rectal Cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Brit J Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2010.06.017","article-title":"Long\u2013Term Quality of Life in Patients With Rectal Cancer Treated With Preoperative (Chemo)\u2013Radiotherapy Within a Randomized Trial","volume":"14","author":"Tiva","year":"2010","journal-title":"Cancer Radiother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.07.007","article-title":"Late Patient\u2013Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase Iii Study","volume":"81","author":"Braendengen","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24247","article-title":"Preoperative Chemoradiation Versus Radiation Alone for Stage II and III Resectable Rectal Cancer: A Systematic Review and Meta\u2013Analysis","volume":"124","author":"Ceelen","year":"2009","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.radonc.2014.09.002","article-title":"Clinical and Dosimetric Predictors of Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemoradiotherapy","volume":"113","author":"Yang","year":"2014","journal-title":"Radiother Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13014\u2013015\u20130454\u20130","article-title":"Can Dosimetric Parameters Predict Acute Hematologic Toxicity in Rectal Cancer Patients Treated With Intensity\u2013Modulated Pelvic Radiotherapy","volume":"10","author":"Wan","year":"2015","journal-title":"Radiat Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11547\u2013015\u20130605\u20132","article-title":"A Prospective Phase II Study of Magnetic Resonance Imaging Guided Hematopoietical Bone Marrow\u2013Sparing Intensity\u2013Modulated Radiotherapy With Concurrent Chemotherapy for Rectal Cancer","volume":"121","author":"Wang","year":"2016","journal-title":"Radiol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0360\u20133016(94)00430\u2013S","article-title":"Hematopoietic Stem Cell Compartment: Acute and Late Effects of Radiation Therapy and Chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","article-title":"Hematopoietic tissue","volume-title":"Radiation pathology","author":"Fajardo","year":"2001"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1088\/0031\u20139155\/5\/3\/302","article-title":"The Distribution of Active Bone Marrow in the Adult","volume":"5","author":"Ellis","year":"1961","journal-title":"Phys Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.03.018","article-title":"Dosimetric Predictors of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With Concurrent Cisplatin and Intensity\u2013Modulated Pelvic Radiotherapy","volume":"66","author":"Mell","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity\u2013Modulated Radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/1097-0142(197309)32:3<699::aid-cncr2820320324>3.0.co;2-v","article-title":"Bone Marrow Regeneration and Extension After Extended Field Irradiation in Hodgkin\u2019s Disease","volume":"32","author":"Rubin","year":"1973","journal-title":"Cancer\u2013Am Cancer Soc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197809)42:3<1057::aid-cncr2820420304>3.0.co;2-p","article-title":"Bone Marrow Regeneration Following Large Field Radiation: Influence of Volume, Age, Dose, and Time","volume":"42","author":"Sacks","year":"1978","journal-title":"Cancer\u2013Am Cancer Soc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0167\u20138140(84)80062\u20136","article-title":"The Paradoxes in Patterns and Mechanism of Bone Marrow Regeneration After Irradiation. 1. Different Volumes and Doses","volume":"2","author":"Scarantino","year":"1984","journal-title":"Radiother Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196409)17:9<1144::aid-cncr2820170907>3.0.co;2-4","article-title":"Long\u2013Term Effects of Therapeutic Irradiation Upon Bone Marrow","volume":"17","author":"Sykes","year":"1964","journal-title":"Cancer\u2013Am Cancer Soc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.11.010","article-title":"Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With Chemoradiotherapy","volume":"79","author":"Rose","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.12.072","article-title":"Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients Treated With Intensity\u2013Modulated Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal","volume":"84","author":"Bazan","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.radonc.2016.07.017","article-title":"International Consensus Guidelines on Clinical Target Volume Delineation in Rectal Cancer","volume":"120","author":"Valentini","year":"2016","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.11.012","article-title":"Prospective Randomized Double\u2013Blind Pilot Study of Site\u2013Specific Consensus Atlas Implementation for Rectal Cancer Target Volume Delineation in the Cooperative Group Setting","volume":"79","author":"Fuller","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.05.071","article-title":"Radiation Dose\u2013Volume Effects in the Stomach and Small Bowel","volume":"76","author":"Kavanagh","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.05.041","article-title":"Fat Composition Changes in Bone Marrow During Chemotherapy and Radiation Therapy","volume":"90","author":"Carmona","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.027","article-title":"Bone Marrow\u2013Sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage IB\u2013IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC\u20132)","volume":"97","author":"Mell","year":"2017","journal-title":"Int J Radiat Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.646211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:01:39Z","timestamp":1619107299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.646211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":28,"alternative-id":["10.3389\/fonc.2021.646211"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.646211","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"646211"}}